Haemochromatosis and Periodontitis

Periodontitis is a chronic inflammatory disease that affects tissues surrounding the teeth. It is strongly associated with the major pathogenic "red complex", including Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola1 and thus is considered an infection. Recent advances in the pathogenesis of periodontal disease have suggested that polymicrobial synergy and microbiota dysbiosis together with a dysregulated immune response can induce inflammation-mediated damage in periodontal tissues2-4. Interestingly, currently periodontitis is associated with a growing number of systemic diseases, including cardiovascular diseases, adverse pregnancy outcomes, diabetes5-7 and hereditary haemochromatosis8.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemochromatosis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Iron Metabolism Disorders Iron Overload Metabolic Diseases Metabolism, Inborn Errors Metal Metabolism, Inborn Errors Nutritional and Metabolic Diseases

Age range

35 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rennes University Hospital

Rennes, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged 35 to 64 years with homozygosity hemochromatosis C282Y
Patients regularly enrolled in a health insurance plan
Patients with at least 10 natural teeth
Patients who have given informed written, dated and signed consent

Exclusion criteria

Diabetic patients
Simultaneous participation in another study
Pregnant or lactating women
The incapacitated persons and persons deprived of their liberty
Patients who do not speak French, both written and spoken
Patients previously included in this trial
Patients with heart valves or endovascular equipment (risk of infective endocarditis ...)
Patients with a history of maxillofacial surgery
Patients whose oral status is considered incompatible with entry into the study, at the discretion of the investigator
Patients on drugs that can cause gingival hypertrophy, such as Hydantoins (phenytoin), Dihydropyridines, Diltiazem or Ciclosporin
Patients on medication that can cause gingival bleeding (anticoagulants, antiplatelet agents and aspirin).

Treatment and study plan

dental probes

Diagnostic Test

Measurement of the depth of the periodontal pockets and clinical loss

Primary outcomes

prevalence of periodontal diseases

Time frame: 2 years

To evaluate the prevalence of periodontal diseases in patients with hemochromatosis at the time of diagnosis and / or their usual therapeutic

Sponsors and collaborators

Lead sponsor

Rennes University Hospital

Other

Registry information

Acronym: HEMOPARO

Important dates

Study start: 2010
Primary completion: 2011
Study completion: 2011
First posted: Jul 5, 2019
Registry last updated: Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed